Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 31, 2025

Glucocorticoids unleash immune-dependent melanoma control through inhibition of the GARP/TGF-β axis

View Full Paper
Ask AI
Bookmark
Share

Authors

CECharles H. EarnshawPDPamela DunnSCShih‐Chieh Chiang

Discussion

Loading...

Member takes

Overview

Experimental treatment shows glucocorticoids improve tumor control in melanoma by disrupting GARP/TGF-β signaling.

Key Points

  • Glucocorticoids promote cytotoxic T lymphocyte-mediated tumor control in a melanoma model.
  • Inhibition of GARP downregulated TGF-β signaling, enhancing immune responses against tumors.
  • Patients with high glucocorticoid receptor expression exhibited better outcomes compared to others.
  • Elevated GARP expression indicates poor survival chances, highlighting its potential as a therapeutic target.

Cite This Study

Earnshaw et al. (2025) studied this question.

synapsesocial.com/papers/689a094be6551bb0af8cf461https://doi.org/10.1101/2025.07.24.666619
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dynamic allostery drives autocrine and paracrine TGF-β signaling2024 · 56 citations
  2. 2Selective Persistence of Dermal CD8+ T Cells in Lesional Plaque Psoriasis after Clobetasol‐17 Propionate Treatment2004 · 16 citations
  3. 3Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes2013 · 80 citations
  4. 4STING pathway agonism as a cancer therapeutic2019 · 329 citations
  5. 5Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations2022 · 130 citations